A research conducted by the UAB demonstrates that mice suffering from Alzheimer's also have substantial malfunctions in small blood vessels, mainly affecting female mice, and find a correlation between the state of arteries and levels of anxious behaviours, both in normal ageing and in those with the disease.
According to the annual report of the European Patent Office, the UAB maintains its lead, for third consecutive year, of Spanish universities applying for patents, with a total of 26 European Patent applications.
The Planttes application is a citizen science project which aims to encourage people to identify and locate on a map the existence of allergy-causing plants and indicate their phenological state.
Smart-4-Fabry is a project funded by the European Commission within the Horizon 2020 Research and Innovation program with € 5.8 M for 4 years, which aims to develop a new nanomedicine for the treatment of the Fabry rare disease.
Researchers from the CVC-UAB and the University of Florence have developed a new technique based on an algorithm which allows estimating the number of people in large crowds through images with more precision than before, with a 10% to 20% margin of error.
The UAB Graduate School has organised a competition for its PhD students. The challenge consists in an oral presentation of their research, lasting a maximum of four minutes and aimed at a general public. All those interested can sign up from 28 February to 22 March.
The biopharmaceutical company, Ability Pharmaceuticals, a member of the UAB Research Park, has announced that the United States Food and Drug Administration (FDA) has approved a phase 1/2 study to assess the efficacy and safety of ABTL0812.
The UAB received €34.4M from the Horizon 2020 programme for 73 projects in the 2014-2017 period. This data makes it third in funding for Spanish universities, following the technical universities of Catalonia (UPC) and Madrid (UPM).
The device contains living cells and mimics the structure and physiological conditions of the blood–retinal barrier; it also enables testing molecules in vitro and studying diseases such as diabetic retinopathy.